Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Gattermann,N., Finelli,C., Della Porta,M., Fénaux,P., Ganser,A.G., Guerci-Bresler,A., Schmid,M.L., Taylor,K.M., Vassilieff,D., Habr,D., Domokos,G., Roubert,B., Rose,C.S., Aǧaoǧlu,L., Alimena,G., Alonso,D., Amé,S., Angelucci,E., Arrizabalaga,B., Athanasiou-Metaxa,M., Augustson,B.M., Aydınok,Y., Baba,A.A., Baccarani,M., Beck,J.T., Béris,P.H., Beyne-Rauzy,O., Birgens,H.S., B́ordessoule,D., Borgna-Pignatti,C., Bosly,A.E., Bouabdallah,K., Bowden,D.K., Bowen,D.T., Bron,D.G., Cappellini,M.D.O., Capra,M.E.Z., Cartron,G., Cazzola,M., Chalkias,C., Chan,L., Chancharunee,S., Chapman,C.S., Charoenkwan,P., Chasapopoulou,E., Chèze,S., Chuansumrit,A., Cianciulli,P., Dauriac,C., Delforge,M., Dölken,G., Dombret,H., Duyster,J., Economopoulos,T.H., Ehninger,G.E., Elalfy,M.S., El Beshlawy,A., Enggaard,L., Fillet,G., Filosa,A., Forni,G.L., Galanello,R., Gastl,G.A., Giraudier,S., Goldfarb,A.W., Grigg,A.P., Gümrük,F.U., Ha,S.Y., Haase,D., Heinrich,B., Hertzberg,M.S., Ho,J., Hsu,H., Huang,S., Hunault-Berger,M., Inusa,B.P.D., Jaulmes,D., Jensen,J.M., Kattamis,A.C., Kilinç,Y., Kim,K., Kinsey,S.E., Kjeldsen,L., Koren,A., Lai,M., Lai,Y., Lee,J., Lee,K., Lee,S., Legros,L., Li,C., Li,Q., Lin,K., Linkesch,W.M., Lübbert,M., Lutz,D., Mohamed Thalha,A.J., Mufti,G.J., Muus,P.K., Nobile,F., Papadopoulos,N.T., Perrotta,S., Petrini,M.T., Pfeilstöcker,M., Piga,A.M., Poole,J.E., Porter,J.B., Pungolino,E.M., Quarta,G., Ravoet,C., Jolimont Lobbes,H.H., Remacha,A.F., Roy,L., Saglio,G.G., Sanz,G.F., Schmugge,M., Schots,H., Secchi,G., Seymour,J.F., Shah,F.T., Shah,H.N., Shen,Z., Slama,B., Sutcharitchan,P., Taher,A.T., Tamary,H., Tesch,H.J., Thein,S.L., Troncy,J., Villegas,A.M., Viprakasit,V., Wainwright,L., Waßmann,B., Wettervald,M., Will,A.M., Wörmann,B.J., Wright,J.G., Yeh,S., Yoon,S., Zoumbos,N.C., Zweegman,S.
Format: Article
Published: Elsevier Limited 2015
Subjects:
Online Access:http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955268192&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38178
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-38178
record_format dspace
spelling th-cmuir.6653943832-381782015-06-16T07:46:29Z Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study Gattermann,N. Finelli,C. Della Porta,M. Fénaux,P. Ganser,A.G. Guerci-Bresler,A. Schmid,M.L. Taylor,K.M. Vassilieff,D. Habr,D. Domokos,G. Roubert,B. Rose,C.S. Aǧaoǧlu,L. Alimena,G. Alonso,D. Amé,S. Angelucci,E. Arrizabalaga,B. Athanasiou-Metaxa,M. Augustson,B.M. Aydınok,Y. Baba,A.A. Baccarani,M. Beck,J.T. Béris,P.H. Beyne-Rauzy,O. Birgens,H.S. B́ordessoule,D. Borgna-Pignatti,C. Bosly,A.E. Bouabdallah,K. Bowden,D.K. Bowen,D.T. Bron,D.G. Cappellini,M.D.O. Capra,M.E.Z. Cartron,G. Cazzola,M. Chalkias,C. Chan,L. Chancharunee,S. Chapman,C.S. Charoenkwan,P. Chasapopoulou,E. Chèze,S. Chuansumrit,A. Cianciulli,P. Dauriac,C. Delforge,M. Dölken,G. Dombret,H. Duyster,J. Economopoulos,T.H. Ehninger,G.E. Elalfy,M.S. El Beshlawy,A. Enggaard,L. Fillet,G. Filosa,A. Forni,G.L. Galanello,R. Gastl,G.A. Giraudier,S. Goldfarb,A.W. Grigg,A.P. Gümrük,F.U. Ha,S.Y. Haase,D. Heinrich,B. Hertzberg,M.S. Ho,J. Hsu,H. Huang,S. Hunault-Berger,M. Inusa,B.P.D. Jaulmes,D. Jensen,J.M. Kattamis,A.C. Kilinç,Y. Kim,K. Kinsey,S.E. Kjeldsen,L. Koren,A. Lai,M. Lai,Y. Lee,J. Lee,K. Lee,S. Legros,L. Li,C. Li,C. Li,Q. Lin,K. Linkesch,W.M. Lübbert,M. Lutz,D. Mohamed Thalha,A.J. Mufti,G.J. Muus,P.K. Nobile,F. Papadopoulos,N.T. Perrotta,S. Petrini,M.T. Pfeilstöcker,M. Piga,A.M. Poole,J.E. Porter,J.B. Pungolino,E.M. Quarta,G. Ravoet,C. Jolimont Lobbes,H.H. Remacha,A.F. Roy,L. Saglio,G.G. Sanz,G.F. Schmugge,M. Schots,H. Secchi,G. Seymour,J.F. Shah,F.T. Shah,H.N. Shen,Z. Slama,B. Sutcharitchan,P. Taher,A.T. Tamary,H. Tesch,H.J. Thein,S.L. Troncy,J. Villegas,A.M. Viprakasit,V. Wainwright,L. Waßmann,B. Wettervald,M. Will,A.M. Wörmann,B.J. Wright,J.G. Yeh,S. Yoon,S. Zoumbos,N.C. Zweegman,S. Cancer Research Hematology Oncology The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. © 2010 Elsevier Ltd. 2015-06-16T07:46:29Z 2015-06-16T07:46:29Z 2010-09-01 Article 01452126 2-s2.0-77955268192 10.1016/j.leukres.2010.03.009 20451251 http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955268192&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38178 Elsevier Limited
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Cancer Research
Hematology
Oncology
spellingShingle Cancer Research
Hematology
Oncology
Gattermann,N.
Finelli,C.
Della Porta,M.
Fénaux,P.
Ganser,A.G.
Guerci-Bresler,A.
Schmid,M.L.
Taylor,K.M.
Vassilieff,D.
Habr,D.
Domokos,G.
Roubert,B.
Rose,C.S.
Aǧaoǧlu,L.
Alimena,G.
Alonso,D.
Amé,S.
Angelucci,E.
Arrizabalaga,B.
Athanasiou-Metaxa,M.
Augustson,B.M.
Aydınok,Y.
Baba,A.A.
Baccarani,M.
Beck,J.T.
Béris,P.H.
Beyne-Rauzy,O.
Birgens,H.S.
B́ordessoule,D.
Borgna-Pignatti,C.
Bosly,A.E.
Bouabdallah,K.
Bowden,D.K.
Bowen,D.T.
Bron,D.G.
Cappellini,M.D.O.
Capra,M.E.Z.
Cartron,G.
Cazzola,M.
Chalkias,C.
Chan,L.
Chancharunee,S.
Chapman,C.S.
Charoenkwan,P.
Chasapopoulou,E.
Chèze,S.
Chuansumrit,A.
Cianciulli,P.
Dauriac,C.
Delforge,M.
Dölken,G.
Dombret,H.
Duyster,J.
Economopoulos,T.H.
Ehninger,G.E.
Elalfy,M.S.
El Beshlawy,A.
Enggaard,L.
Fillet,G.
Filosa,A.
Forni,G.L.
Galanello,R.
Gastl,G.A.
Giraudier,S.
Goldfarb,A.W.
Grigg,A.P.
Gümrük,F.U.
Ha,S.Y.
Haase,D.
Heinrich,B.
Hertzberg,M.S.
Ho,J.
Hsu,H.
Huang,S.
Hunault-Berger,M.
Inusa,B.P.D.
Jaulmes,D.
Jensen,J.M.
Kattamis,A.C.
Kilinç,Y.
Kim,K.
Kinsey,S.E.
Kjeldsen,L.
Koren,A.
Lai,M.
Lai,Y.
Lee,J.
Lee,K.
Lee,S.
Legros,L.
Li,C.
Li,C.
Li,Q.
Lin,K.
Linkesch,W.M.
Lübbert,M.
Lutz,D.
Mohamed Thalha,A.J.
Mufti,G.J.
Muus,P.K.
Nobile,F.
Papadopoulos,N.T.
Perrotta,S.
Petrini,M.T.
Pfeilstöcker,M.
Piga,A.M.
Poole,J.E.
Porter,J.B.
Pungolino,E.M.
Quarta,G.
Ravoet,C.
Jolimont Lobbes,H.H.
Remacha,A.F.
Roy,L.
Saglio,G.G.
Sanz,G.F.
Schmugge,M.
Schots,H.
Secchi,G.
Seymour,J.F.
Shah,F.T.
Shah,H.N.
Shen,Z.
Slama,B.
Sutcharitchan,P.
Taher,A.T.
Tamary,H.
Tesch,H.J.
Thein,S.L.
Troncy,J.
Villegas,A.M.
Viprakasit,V.
Wainwright,L.
Waßmann,B.
Wettervald,M.
Will,A.M.
Wörmann,B.J.
Wright,J.G.
Yeh,S.
Yoon,S.
Zoumbos,N.C.
Zweegman,S.
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
description The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. © 2010 Elsevier Ltd.
format Article
author Gattermann,N.
Finelli,C.
Della Porta,M.
Fénaux,P.
Ganser,A.G.
Guerci-Bresler,A.
Schmid,M.L.
Taylor,K.M.
Vassilieff,D.
Habr,D.
Domokos,G.
Roubert,B.
Rose,C.S.
Aǧaoǧlu,L.
Alimena,G.
Alonso,D.
Amé,S.
Angelucci,E.
Arrizabalaga,B.
Athanasiou-Metaxa,M.
Augustson,B.M.
Aydınok,Y.
Baba,A.A.
Baccarani,M.
Beck,J.T.
Béris,P.H.
Beyne-Rauzy,O.
Birgens,H.S.
B́ordessoule,D.
Borgna-Pignatti,C.
Bosly,A.E.
Bouabdallah,K.
Bowden,D.K.
Bowen,D.T.
Bron,D.G.
Cappellini,M.D.O.
Capra,M.E.Z.
Cartron,G.
Cazzola,M.
Chalkias,C.
Chan,L.
Chancharunee,S.
Chapman,C.S.
Charoenkwan,P.
Chasapopoulou,E.
Chèze,S.
Chuansumrit,A.
Cianciulli,P.
Dauriac,C.
Delforge,M.
Dölken,G.
Dombret,H.
Duyster,J.
Economopoulos,T.H.
Ehninger,G.E.
Elalfy,M.S.
El Beshlawy,A.
Enggaard,L.
Fillet,G.
Filosa,A.
Forni,G.L.
Galanello,R.
Gastl,G.A.
Giraudier,S.
Goldfarb,A.W.
Grigg,A.P.
Gümrük,F.U.
Ha,S.Y.
Haase,D.
Heinrich,B.
Hertzberg,M.S.
Ho,J.
Hsu,H.
Huang,S.
Hunault-Berger,M.
Inusa,B.P.D.
Jaulmes,D.
Jensen,J.M.
Kattamis,A.C.
Kilinç,Y.
Kim,K.
Kinsey,S.E.
Kjeldsen,L.
Koren,A.
Lai,M.
Lai,Y.
Lee,J.
Lee,K.
Lee,S.
Legros,L.
Li,C.
Li,C.
Li,Q.
Lin,K.
Linkesch,W.M.
Lübbert,M.
Lutz,D.
Mohamed Thalha,A.J.
Mufti,G.J.
Muus,P.K.
Nobile,F.
Papadopoulos,N.T.
Perrotta,S.
Petrini,M.T.
Pfeilstöcker,M.
Piga,A.M.
Poole,J.E.
Porter,J.B.
Pungolino,E.M.
Quarta,G.
Ravoet,C.
Jolimont Lobbes,H.H.
Remacha,A.F.
Roy,L.
Saglio,G.G.
Sanz,G.F.
Schmugge,M.
Schots,H.
Secchi,G.
Seymour,J.F.
Shah,F.T.
Shah,H.N.
Shen,Z.
Slama,B.
Sutcharitchan,P.
Taher,A.T.
Tamary,H.
Tesch,H.J.
Thein,S.L.
Troncy,J.
Villegas,A.M.
Viprakasit,V.
Wainwright,L.
Waßmann,B.
Wettervald,M.
Will,A.M.
Wörmann,B.J.
Wright,J.G.
Yeh,S.
Yoon,S.
Zoumbos,N.C.
Zweegman,S.
author_facet Gattermann,N.
Finelli,C.
Della Porta,M.
Fénaux,P.
Ganser,A.G.
Guerci-Bresler,A.
Schmid,M.L.
Taylor,K.M.
Vassilieff,D.
Habr,D.
Domokos,G.
Roubert,B.
Rose,C.S.
Aǧaoǧlu,L.
Alimena,G.
Alonso,D.
Amé,S.
Angelucci,E.
Arrizabalaga,B.
Athanasiou-Metaxa,M.
Augustson,B.M.
Aydınok,Y.
Baba,A.A.
Baccarani,M.
Beck,J.T.
Béris,P.H.
Beyne-Rauzy,O.
Birgens,H.S.
B́ordessoule,D.
Borgna-Pignatti,C.
Bosly,A.E.
Bouabdallah,K.
Bowden,D.K.
Bowen,D.T.
Bron,D.G.
Cappellini,M.D.O.
Capra,M.E.Z.
Cartron,G.
Cazzola,M.
Chalkias,C.
Chan,L.
Chancharunee,S.
Chapman,C.S.
Charoenkwan,P.
Chasapopoulou,E.
Chèze,S.
Chuansumrit,A.
Cianciulli,P.
Dauriac,C.
Delforge,M.
Dölken,G.
Dombret,H.
Duyster,J.
Economopoulos,T.H.
Ehninger,G.E.
Elalfy,M.S.
El Beshlawy,A.
Enggaard,L.
Fillet,G.
Filosa,A.
Forni,G.L.
Galanello,R.
Gastl,G.A.
Giraudier,S.
Goldfarb,A.W.
Grigg,A.P.
Gümrük,F.U.
Ha,S.Y.
Haase,D.
Heinrich,B.
Hertzberg,M.S.
Ho,J.
Hsu,H.
Huang,S.
Hunault-Berger,M.
Inusa,B.P.D.
Jaulmes,D.
Jensen,J.M.
Kattamis,A.C.
Kilinç,Y.
Kim,K.
Kinsey,S.E.
Kjeldsen,L.
Koren,A.
Lai,M.
Lai,Y.
Lee,J.
Lee,K.
Lee,S.
Legros,L.
Li,C.
Li,C.
Li,Q.
Lin,K.
Linkesch,W.M.
Lübbert,M.
Lutz,D.
Mohamed Thalha,A.J.
Mufti,G.J.
Muus,P.K.
Nobile,F.
Papadopoulos,N.T.
Perrotta,S.
Petrini,M.T.
Pfeilstöcker,M.
Piga,A.M.
Poole,J.E.
Porter,J.B.
Pungolino,E.M.
Quarta,G.
Ravoet,C.
Jolimont Lobbes,H.H.
Remacha,A.F.
Roy,L.
Saglio,G.G.
Sanz,G.F.
Schmugge,M.
Schots,H.
Secchi,G.
Seymour,J.F.
Shah,F.T.
Shah,H.N.
Shen,Z.
Slama,B.
Sutcharitchan,P.
Taher,A.T.
Tamary,H.
Tesch,H.J.
Thein,S.L.
Troncy,J.
Villegas,A.M.
Viprakasit,V.
Wainwright,L.
Waßmann,B.
Wettervald,M.
Will,A.M.
Wörmann,B.J.
Wright,J.G.
Yeh,S.
Yoon,S.
Zoumbos,N.C.
Zweegman,S.
author_sort Gattermann,N.
title Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
title_short Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
title_full Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
title_fullStr Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
title_full_unstemmed Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
title_sort deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year epic study
publisher Elsevier Limited
publishDate 2015
url http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955268192&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38178
_version_ 1681421426264899584